1. Home
  2. QTTB

as 05-22-2024 3:31pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 362.6M IPO Year: N/A
Target Price: $49.67 AVG Volume (30 days): 33.2K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -32.43 EPS Growth: N/A
52 Week Low/High: $8.24 - $32.88 Next Earning Date: 05-09-2024
Revenue: $354,000 Revenue Growth: -93.39%
Revenue Growth (this year): -11.76% Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Q32 Bio Inc. Common Stock (QTTB)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Michaud Charles Jr QTTB See Remarks Mar 25 '24 Sell $24.20 75 $1,815.00 927 SEC Form 4
Alloway Paul QTTB See Remarks Jan 3 '24 Sell $0.57 7,280 $4,120.48 28,036 SEC Form 4
TZIANABOS ARTHUR QTTB Director Jan 1 '24 Sell $0.57 13,037 $7,445.43 128,778 SEC Form 4